4/A//SEC Filing
10X Fund, L.P. 4/A
Accession 0001493152-22-022804
CIK 0001133416other
Filed
Aug 14, 8:00 PM ET
Accepted
Aug 15, 3:03 PM ET
Size
6.4 KB
Accession
0001493152-22-022804
Insider Transaction Report
Form 4/AAmended
10X Fund, L.P.
10% Owner
Transactions
- Sale
Common Stock
2022-07-27$2.09/sh−10,000$20,870→ 6,168,940 total
Footnotes (2)
- [F1]Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan.
- [F2]10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Documents
Issuer
GALECTIN THERAPEUTICS INC
CIK 0001133416
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001453356
Filing Metadata
- Form type
- 4/A
- Filed
- Aug 14, 8:00 PM ET
- Accepted
- Aug 15, 3:03 PM ET
- Size
- 6.4 KB